Daxor Corporation (NASDAQ:DXR) announced the receipt of a $550K matching-fund extension from the U.S. Defense Health Agency (DHA) for its Phase II SBIR contract. This additional funding will support the incorporation of...
BioRestorative Therapies (NASDAQ:BTRX) announced that Francisco Silva, the company’s chief scientist and vice president of research and development, has been appointed section editor of the newly launched Regenerative...
Lake Street initiated coverage of Profound Medical (NASDAQ:PROF; TSX:PRN) with a “buy” rating and $16.50 price target. The stock closed at $10.19 on July 22. Analyst Ben Haynor writes that with reimbursement of TULSA...
Closely-held Cytel, a global leader in clinical trial design and software, announced today its strategic partnership with OneMedNet (NASDAQ:ONMD) to enhance data-driven healthcare solutions. The partnership will...
Anebulo Pharmaceuticals (NASDAQ:ANEB) has been awarded the first tranche of a two-year, $1.9 million NIDA grant to develop intravenous selonabant for treating acute cannabis-induced toxicity, including CNS depression in...
Sernova (TSX:SVA; OTCQB:SEOVF; FSE/XETRA:PSH) has named Jonathan Rigby as executive chairman, effective immediately. Mr. Rigby, previously a director with the company, replaces chairman Brett Whalen, who has resigned...
Clearmind Medicine (NASDAQ:CMND; FSE:CWYO) announced it has filed an additional patent application with the USPTO for the novel proprietary composition of its MEAI compound for treating metabolic syndrome and obesity...
Alto Neuroscience (NYSE:ANRO) announced the completion of enrollment in its Phase 2b study evaluating ALTO-100 in 300 adults with major depressive disorder (MDD) across 34 U.S. sites. The randomized, double-blind...
After market close today, Stifel upgraded Profound Medical (NASDAQ:PROF; TSX:PRN) to “buy” from “hold” and raised its price target to $12 from $9 in response to the U.S. Centers for Medicare and Medicaid Services (CMS)...
EF Hutton launched coverage of Citius Pharmaceuticals (NASDAQ:CTXR) a “buy” rating and $6 target price. The stock closed at $0.7340 on July 12. Citius is a pharmaceutical/biotechnology company with two late-stage assets...
Raymond James upgraded Alpha Cognition (CSE:ACOG) to “outperform” from “market perform” and raised its price target to C$2 from C$1 with the company’s PDUFA date less than 2 weeks away (July 27th). The stock closed at...
Profound Medical (NASDAQ:PROF; TSX:PRN) announced that the U.S. Centers for Medicare and Medicaid Services has issued proposed rules establishing, for the first time, a Category 1 CPT code for the Transurethral...